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Abstract
Mast cells are tissue-resident, innate immune cells present in most tissues of
the body and are important effector and immunomodulatory cells. Differentiated
mast cells typically are characterized by the surface expression of the receptors
KIT and FcεRI, the latter especially being important for stimulation through IgE
antibodies, although these cells have the ability to respond to a wide variety of
environmental signals, to which they can variably react by releasing pre-stored
or  –synthesized mediators or both. Since mast cells terminate theirde novo
differentiation in their tissue of residence in response to specific
microenvironmental cues, each tissue may comprise unique mast cell
subtypes, and responses are tailored to the danger signals that are likely to be
encountered in each anatomical location. From a transcriptional point of view,
these cells therefore must be endowed with epigenetic and transcriptional
programs that allow them to maintain a stable identity and at the same time
allow sufficient plasticity to adapt to different environmental challenges. In this
commentary, we highlight some of the recent findings that advanced our
understanding of the transcriptional and epigenetic programs regulating mast
cell functions.
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Introduction: how many types of mast cells are there 
and what do they do?
Mast cells are one of the innate immune cell types involved in 
the first line of defense from pathogens that attempt to breach the 
epithelial barriers of our organism1,2. Indeed, these cells are most 
notably located in vascularized tissues, including the skin, the 
mucosa of the lungs, and the gastrointestinal tract, where they 
reside primarily at the interface with the environment, namely 
beneath the epithelial surface. The clearest examples of immune-
related responses in which mast cells play a key role are in the 
context of allergy3–6 as well as in immunity against parasites7. 
However, these cells have been involved in a plethora of proc-
esses, either protective of (tissue homeostasis and wound healing) 
or damaging to (chronic inflammation and cancer and autoim-
mune diseases2,8,9) the organism, and some of the proposed 
functions of these cells have also become a matter of debate1,10. 
The main reasons for the difficulties in obtaining concluding 
evidence about mast cell functions in vivo include the complica-
tions linked to studying tissue-resident cells as well as the com-
plexity of mast cell phenotypes and responses. Indeed, mast cells 
carry a wide repertoire of receptors and can be activated by an 
impressive number of different stimuli11 (Figure 1), which can 
lead to a battery of different responses that may occur together or 
independently12. These include degranulation with release of 
mediators pre-stored in cytoplasmic granules1,2, de novo synthesis 
of cytokines and chemokines, release of exosomes that may act 
over long distances13, and even release of DNA extracellular 
traps14. These widespread possibilities of stimuli and responses, 
together with the fact that these are exclusively tissue-resident 
cells difficult to extract in sufficient number without inducing 
any modification to their biology, have made the task of pinpoint-
ing their main functions remarkably challenging. For example, a 
study aimed at defining the human mast cell transcriptome clearly 
showed how mast cell transcriptional responses change dramati-
cally upon in vitro culture with interleukin-4 (IL-4) and stem 
cell factor15 as compared with freshly isolated mast cells from 
human skin16. Transcriptional changes reflected primarily meta-
bolic activation, most likely linked to culture-induced cell cycle 
progression; however, other transcriptional changes (such as the 
induction of genes characteristic of other lineages) were sugges-
tive of problems in fully maintaining cell identity in vitro. To add 
to this complexity, circulating human mast cell progenitors are 
very rare and difficult to differentiate in vitro, and so far no 
in vitro system has been able to recapitulate the wide variety of 
phenotypes or states that are likely to exist in vivo. Indeed, the 
complexity of signals and microenvironmental cues that lead to 
the migration of mast cell progenitors to specific tissues remains 
to be fully unraveled, although these cells are clearly influenced by 
changes in their cytokine milieu and by the presence of activating 
factors12.
Besides the challenges of studying mast cells, why should we care 
about these cells and how they are regulated? Studying mast cells 
has the obvious implication of a better understanding of mecha-
nisms that are involved in allergy and asthma as well as in mast 
cell–proliferative diseases17 (Figure 2), and as our technological 
resources are improving at an unprecedented speed, we are also 
becoming increasingly able to gain more mechanistic details on 
their functions. For example, the important role of mast cells in 
eradicating infections by intestinal nematodes has been known for 
quite some time; however, the underlying mechanism was unclear. 
A recent study showed that mast cells respond to ATP released 
by intestinal epithelial cells damaged during parasite infection by 
secreting IL-3318. Mast cell–derived IL-33 in turn activated group 
2 innate lymphoid cells (ILC2) to produce IL-13, leading to goblet 
cell hyperplasia and worm expulsion. Similarly, mast cells have an 
established role in allergic reactions, and their contribution to such 
responses is dependent on the acquisition of antigen-specific IgE 
antibodies that are bound to the high-affinity IgE receptor (FcεRI) 
on the cell surface. However, it was only recently elucidated that 
for mast cells to acquire IgE antibodies from the blood, they must 
display a preferential perivascular location, which enabled direct 
access to the blood and sampling of the intravascular lumen through 
cellular projections19. Also, mast cells turned out to have a crucial 
role in orchestrating the exfoliation of epithelial cells in the bac-
terially infected bladder, thereby inducing an important defense 
mechanism aimed at reducing bacterial burden20. Indeed, IL-1β 
produced by bacterially exposed bladder epithelial cells potently 
recruited mast cells to the site of infection; uptake of the released 
mast cell granules by epithelial cells was followed by the release of 
the mast cell protease Mcpt4 and caspase-1 activation, eventually 
leading to cell death20. Although the specific signals that induced 
mast cell degranulation in the infected bladder remain to be 
elucidated, this study highlighted how mast cells can influence the 
outcome of many different physiological responses. Mast cells were 
also shown to suppress humoral and cell-mediated responses in the 
bladder, through the production of the anti-inflammatory cytokine 
IL-10, most likely in an attempt to protect the organ from excessive 
tissue damage21. Whether the same cell can switch from a pro- to an 
anti-inflammatory phenotype during the course of an infection in 
the bladder, or instead different subsets are involved, remains to be 
determined. Interestingly, mast cell–derived IL-10 was also shown 
to modulate contact hypersensitivity reactions, although the extent 
of IL-10 production (and thereby the final contribution of mast cells 
to the amplification or attenuation of tissue pathology) appeared 
to be variable depending on the severity of the model of contact 
hypersensitivity used3,5,6.
Transcription factors in mast cells
Many studies have assessed the transcriptional profile of mast 
cells, from both human and mouse, although for the most part 
they used cultured cells, and only in rare cases was a comparison 
with ex-vivo–derived tissue cells attempted16. Since mast cells dif-
ferentiate in local tissue niches, it is probable that they adaptively 
develop characteristic features that allow them to best function 
within a given context8,22. Indeed, the fact that tissue mast cells 
can be quite heterogeneous (for example, from the point of view 
of the content of their granules) has been recognized for quite 
some time12,22–24. However, from a transcriptional point of view, 
studying the heterogeneity of tissue mast cells implies the 
ability to extract them directly from various tissues and perform 
transcriptome analyses such as RNA sequencing. In this kind of 
analysis, mast cell heterogeneity may be reflected in differences in 
their gene expression programs and this is exactly what has been 
observed in murine mast cells extracted from different tissues25. 
Indeed, mouse mast cells derived from various anatomical 
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Figure 1. Mast cells and their receptors. Mast cells are highly reactive cells expressing a plethora of receptors with specificity toward 
many types of stimuli. Upon activation, mast cells can release pre-formed mediators stored in cytoplasmic granules, including proteases 
and vasoactive mediators, while cytokines and chemokines can be either pre-stored or de novo–synthesized. The most commonly studied 
pathway for mast cell activation includes the engagement of the high-affinity IgE receptor (FcεRI), and is dependent on the production of 
antigen-specific IgE antibodies by B lymphocytes, in response to interleukin-4 (IL-4) and IL-13 produced by T helper 2 (Th2) lymphocytes26. 
Crosslinking of the FcεRI-bound IgE by antigens results in mast cell degranulation and cytokine production27. Mast cells can also express 
surface receptors for IgG antibodies, namely FcγR, whose engagement can lead to both activating and inhibitory signals, depending on the 
specific receptor involved28. A variety of pathogen recognition receptors (PRRs), including Toll-like receptors (TLRs), are also expressed on 
the mast cell surface. For example, TLR2 is activated by bacterial lipopeptides, while TLR4 is activated by lipopolysaccharide (LPS) binding. 
Notably, TLR-mediated activation does not usually lead to mast cell degranulation, but triggers the production of de novo–synthetized 
mediators such as cytokines and chemokines. Mast cells also express receptors for chemokines, cytokines, and growth factors, essential 
not only for their maturation and differentiation but also to modulate their responses. For example, the KIT receptor binds the stem cell factor 
(SCF), important for mast cell proliferation and maturation11. The MRGPRX2 receptor is activated by a range of ligands, including inflammatory 
peptides and drugs associated with allergic reactions29. Finally, complement receptor-mediated activation of mast cells can be induced by 
different complement components, such as C3a or C5a11. Transcription factors such as PU.1, MITF, GATA and C/EBP family members have 
critical roles in regulating mast cell development and in the maintenance of cell identity30, while transcription factors such as NF-κB, NFAT and 
AP-1 are predominantly involved in the acute regulation of inflammatory genes23.
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Figure 2. Mast cell–related disorders. Diseases associated with mast cells can broadly include disorders associated with extrinsic factors, 
such as the ones mediated by IgE antibodies that, acting through the high-affinity IgE receptor (FcεRI) expressed on the mast cell surface, can 
translate into the development of allergic reactions. Allergies are detrimental immune responses against otherwise innocuous environmental 
antigens, which induce the production of IgE antibodies that can activate mast cells, eventually leading to, for example, allergic rhinitis, 
asthma, and atopic dermatitis26. Excessive allergic reactions can translate into anaphylaxis. Other disorders can instead be cell-intrinsic, 
due to altered biological features of mast cells that lead to uncontrolled responses (mast cell activation syndrome, or MCAS)31 or excessive 
proliferation (systemic and cutaneous mastocytosis, or SM and CM). Potentially, all mast cell disorders can display altered activation and are 
broadly defined as mast cell activation disorders (MCADs), although MCAS represents a subgroup displaying mast cell activation without 
clonal expansion32,33.
locations (peritoneal cavity, ear, tongue, trachea, and esophagus) 
displayed a high degree of heterogeneity across the different 
tissues, although they clustered distinctly from other profiled 
lymphoid and myeloid cell types, including basophils and other 
granulocytes. Some signature genes that specifically character-
ized mast cells included a number of proteases such as Ctsg, 
encoding for cathepsin G; the metalloprotease gene Adamts9; 
and C2, encoding for the complement component C2 of the clas-
sic C3 convertase25. Among the transcription factors, Crebl1, 
Smarca1, and Zfp9 appeared to be relatively specific for mast 
cells, although their role remains unknown, while Mitf, a transcrip-
tion factor crucial for mast cell differentiation and functions34, 
clearly defined mast cells from other cell types. Highlighting 
once again the complications associated with studies of tissue-
resident cells, the authors found that incubating peritoneal mast 
cells in the presence of the digestion enzymes required for tissue 
extraction was already sufficient to alter the expression of more 
than 100 genes, including the gene encoding for the transcrip-
tion factor Egr2. They therefore proceeded to compare enzymati-
cally treated peritoneal mast cells with other mast cell populations 
enzymatically extracted from the tissues. Such analysis revealed 
that, overall, mast cells from the different tissues shared a core 
signature of 128 genes, including genes encoding for proteases 
or involved in metabolic pathways important for the generation 
of the wide repertoire of mediators that characterize mast cells. 
Comparative analysis of cells from the different tissues showed 
that mast cells from the trachea, esophagus, and tongue dis-
played the highest transcriptional similarity, although some spe-
cificity remained. For example, the gene encoding for the protease 
Mcpt1 appeared to be relatively specific for mast cells from the 
esophagus. Peritoneal and skin mast cells appeared to be more 
divergent in their transcriptional profiles, with differential expres-
sion of a number of genes, including the adhesion molecule CD34 
(which was absent in skin mast cells), the transcription factor 
SOX7 (increased in skin mast cells), and the integrin β2, the last 
of which instead was preferentially detected in peritoneal mast 
cells. Interestingly, peritoneal mast cells were characterized by a 
transcriptional signature significantly associated with mitosis, and 
indeed these cells appeared to undergo proliferation even in the 
absence of inflammation25.
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Apart from MITF, other transcription factors that are known to 
positively or negatively impact mast cell differentiation or func-
tion (or both) belong to the GATA, STAT, and C/EBP families 
(reviewed in 23,30) (Figure 1). For instance, STAT5 expression 
was shown to be crucial in modulating mast cell survival in 
response to cytokine signals35, and STAT5 activity in mast cells 
was linked to allergen-induced dermatitis36. Interestingly, sev-
eral transcription factors also showed some level of crosstalk in 
regulating mast cell differentiation and functions: for example, 
C/EBPα and MITF acted antagonistically in the specification 
of the basophil and mast cell lineages37, while STAT5 acted 
upstream of GATA2 in the differentiation pathways leading 
to either mast cells or basophils38. Other transcription factors 
such as HES139, EGR family members40,41, or ZEB242 have also 
been associated with at least some specific aspects of mast cell 
biology23, although their exact role in vivo or their detailed mecha-
nism of action at the genomic level requires further investigation. 
Of note, many of the transcription factors that are involved in mast 
cell activation (NFAT, NF-κB, AP-1, and so on) are also more 
general regulators of inflammatory genes in many immune cell 
types, and they will not be extensively discussed here. We refer the 
reader to a more comprehensive review on this topic23.
Innate immune memory
The cell-intrinsic, short-term memory of an encounter with a 
pathogen or a danger signal43 may be especially relevant for mast 
cells compared with very short-lived cells such as neutrophils and 
basophils. Mast cells are very long-lived cells, retain the abil-
ity to proliferate despite being fully differentiated2, and can even 
replenish and modulate the composition of their granules after 
stimulation44. The process of enhanced innate immune response 
against a secondary encounter with a pathogen, which was clearly 
defined in macrophages and other innate immune cells as “trained 
immunity”45, could influence secondary mast cell responses after 
the first activation and could be important in the modulation 
of protective as well as allergic responses. Mechanistically, 
such innate immune memory is thought to be based mainly on 
epigenetic reprogramming, involving histone modifications, DNA 
methylation, and even the expression of selected microRNAs 
and other non-coding RNAs, which collectively contribute to 
the rewiring of the transcriptional program of the cell upon 
stimulation43,45. However, not many studies addressed the issue of 
cell-intrinsic, long-term changes in mast cell functional programs 
in response to a stimulus. For example, lipopolysaccharide (LPS) 
stimulation of mast cells can induce a state of unresponsiveness 
to a subsequent stimulation which is similar to the endotoxin tol-
erance described for macrophages, thereby probably representing 
a genuine example of mast cell short-term memory46, and some 
crosstalk between IgE and LPS stimulation in mast cells was also 
reported47. However, mast cells can be directly activated by many 
additional stimuli (Figure 1), and whether a true trained immunity 
applies to mast cells for at least some of these stimuli, the rele-
vance of such a process in vivo, and the underlying mechanisms 
are all aspects that require further investigation, especially in view 
of a potentially crucial role in modulating mast cell responses.
Epigenetic control of mast cell responses
Chromatin modifications such as covalent modifications of 
histone tails or DNA methylation are epigenetic mechanisms 
of regulation of transcription, which include all of those mecha-
nisms that influence gene expression by modulating the accessi-
bility of regulatory regions to transcription factors without altering 
the DNA sequence. Epigenetic modifications are critical mecha-
nisms that modulate the interplay of genomic sequences with 
environmental signals, and indeed they have a crucial role during 
development, in the maintenance of cell identity, in cell differen-
tiation, and in regulating acute responses to stimuli. Because of 
the complex networks in which these mechanisms act, and their 
ability to affect the entire genome, epigenetic studies often suffer 
from major obstacles that hinder our mechanistic understanding 
of the biological role of epigenetic modifications48. For instance, 
loss-of-function studies of DNA methyltransferase (DNMT) 
enzymes revealed the unmistakable importance of this epigenetic 
modification during development50,51; however, the molecular 
mechanisms underlying the embryonic or perinatal lethality 
observed in the absence of DNMT enzymes remain far from 
being firmly established. Indeed, distinguishing causality from 
association or direct and indirect effects of chromatin-related 
processes remain major challenges48.
What is the role of epigenetic modifications in regulating mast 
cell biology? In terms of histone modifications, by assessing the 
role of the regulatory subunit ASXL1 of a deubiquitinase com-
plex in hematopoietic differentiation, a recent study showed that 
altered levels of monoubiquitination of lysine 119 on histone 
H2A affected mast cell differentiation51, pointing toward a key 
role for histone modifications in this process. Interestingly, mast 
cells appear to exploit an atypical epigenetic regulatory mecha-
nism, mediated by the endogenously produced protease tryptase 
that not only can be secreted by the cells to affect the extracellular 
milieu but also can translocate into the nucleus of the producing 
cell, where it mediates the cleavage of histone tails, thereby mod-
ulating gene expression52. While some mechanistic aspects (such 
as the regulation of tryptase nuclear translocation) remain to be 
understood, this example further highlights the potential impor-
tance of histone modifications in mast cell biology. Accordingly, 
histone deacetylase inhibitors appeared to impact the prolifera-
tion and viability of pathogenic mast cells derived from patients 
with mast cell–proliferative disorders53. But in general, very few 
studies have investigated the role of histone modifications or 
histone-modifying enzymes in regulating mast cell differentia-
tion and function. Further studies in this direction, especially in 
primary mast cells obtained from tissues, would certainly provide 
further insights about how these cells are regulated and what goes 
wrong during disease.
As for DNA methylation, this process is mediated by DNMT 
enzymes that covalently link a methyl group to cytosines in the 
genomic DNA to give rise to 5-methylcytosine (5mC). Such 
modification can influence gene expression either by interfering 
with the binding of transcription factors and co-regulators to a 
given DNA sequence or by recruiting specific methyl-binding 
proteins54. The importance of this process in transcriptional 
regulation is highlighted not only by the altered developmental 
processes observed in the absence of DNMT enzymes but also 
by the many examples of disease, including hematological malig-
nancies, in which DNMT enzymes are mutated and DNA meth-
ylation is affected55. Methylated cytosines in the genomic DNA 
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can also be oxidized to 5-hydroxymethylcytosine (5hmC) by the 
action of the ten-eleven-translocation enzymes TET1-3 (Figure 3). 
Such modification is usually enriched at enhancer elements 
and correlates with transcription56. DNA methylation–related 
processes are also critical to specifically modulate mast cell dif-
ferentiation and functions; indeed, we found that deletion of the 
mouse Tet2 gene affected primarily mast cell differentiation 
and proliferation57. Interestingly, while cells lacking Tet2 were 
characterized by a very significant hyperproliferation compared 
with wild-type cells, heterozygous cells displayed an interme-
diate phenotype, pointing toward gene-dosage effects. These 
results suggest that somatic TET2 mutations on one allele may be 
sufficient to predispose individuals to excessive mast cell pro-
liferation, although in the absence of additional mutations they 
are insufficient to cause overt disease58,59. Unlike Tet2 ablation, 
deletion of Dnmt3a in the mouse led primarily to unrestrained 
mast cell responses to stimuli, with significantly increased mast 
cell degranulation and activation both in vitro and in in vivo60. 
Importantly, treatment with demethylating agents or down- 
modulation of the expression of another DNMT enzyme reca-
pitulated or even exacerbated these phenotypes, at least in vitro, 
highlighting the key role of DNA methylation–related mecha-
nisms in modulating mast cell activation60,61.
DNA methylation in disease
Mast cell–related diseases manifest in a wide range of disor-
ders displaying activation or proliferative dysregulation or both 
(Figure 2)31,62. In particular, mastocytosis is characterized by the 
abnormal proliferation and accumulation of mast cells in various 
organs and tissues. While the exact cause of mastocytosis 
Figure 3. DNA methylation dynamics. (a) Mechanisms of maintenance and loss of DNA methylation. During DNA replication, DNMT1 
binds hemi-methylated single-stranded DNA (ssDNA) and copies DNA methylation patterns on the newly synthetized DNA strand, thereby 
maintaining the overall DNA methylation landscape across DNA replication and cell division. In the absence of DNMT1, such a process 
is impaired, resulting in the passive dilution of the methyl mark during cell division. While DNMT1 acts as the primary maintenance DNMT 
enzyme during cell division, DNMT3A and DNMT3B also contribute to DNA methylation as de novo DNMTs (namely they do not require a 
hemi-methylated DNA template but also can act on fully unmethylated DNA). (b) DNA methylation and hydroxymethylation. DNMT enzymes 
methylate the 5′ carbon residue on the cytosine ring in DNA, giving rise to 5′-methylcytosine (5mC). Iterative oxidation of the methyl group 
mediated by ten-eleven-translocation (TET) enzymes leads to the formation of 5′-hydroxymethylcytosine, followed by 5′-formylcytosine and 
5′-carboxylcytosine. The latter two modifications are recognized and excised by the thymine-DNA-glycosylase (TGD) enzyme, leaving an 
abasic site in the DNA, which is repaired by base excision repair (BER) mechanisms. Because this process of iterative oxidation leads to the 
substitution of a modified cytosine with an unmodified one, it is also termed TET protein-assisted active DNA demethylation.
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remains unclear, it is frequently associated with mutations in the 
KIT oncogene, most commonly an aspartic acid–to–valine 
substitution at codon 816, causing spontaneous activation of the 
KIT receptor62. One of the first indications that DNA methylation– 
related processes might be important in mast cell biology came 
from the observation that decitabine, a demethylating agent 
used in the clinic for the treatment of myeloproliferative and 
myelodysplastic disorders, induced apoptosis of neoplastic mast 
cells, at least in vitro63. Moreover, mutations in the gene encoding 
for DNMT3A were identified in 3 out of 26 patients with 
systemic mastocytosis64, while TET2 mutations were identified in 
at least 20% of the patients59,64,65, and these correlated with worse 
overall survival64. Accordingly, reduced levels of cytosine modifica-
tions were observed in patients with systemic mastocytosis66, and 
altered DNA methylation patterns were reported in tissues and cells 
of patients with asthma67. However, patient studies are by neces-
sity mostly correlative, and becoming able to distinguish whether 
such changes are cause or consequence or simply associate with a 
certain phenotype can be a daunting task. For example, systemic 
mastocytosis patients carrying TET2 mutations tended to be older 
and have higher monocyte counts64; since inactivating TET2 
mutations also accumulate with age in healthy individuals68,69, 
the boundaries between cause and consequence remain problem-
atic to define. Indeed, a recent mutational analysis of more than 
2,500 human subjects identified mutations in TET2 and DNMT3A 
as the most common age-associated mutations even in healthy 
individuals, and TET2 mutations had a stronger impact on the 
steady increase in hematopoietic clonal expansion compared with 
DNMT3A mutations69. While the effects of these mutations in 
disease and in the normal processes of aging are being uncov-
ered, in the future further studies will certainly lead to a better 
understanding of the exact role of DNA-modifying enzymes and 
epigenetic mechanisms in regulating mast cell functions in the 
context of immune responses and in disease.
Conclusions
Thanks to the development of novel mouse models and to tech-
nological advancements allowing the in vivo visualization of mast 
cells and their in-depth molecular analysis, we are learning more 
about the role of these cells in various models of disease and 
inflammatory responses, and we are also better able to dissect some 
of the mechanistic aspects of such responses. However, despite 
the great advancements in the field in recent years, many of the 
mechanisms and factors underlying mast cell differentiation and 
responses remain poorly defined. In the future, the combination 
of traditional in vitro and single-molecule studies with single-cell 
genomic and genome-wide approaches70 will certainly improve 
our understanding of mast cell subsets and functions, poten-
tially allowing us to analyze them within the physiological con-
text of their microenvironment. Such developing tools will surely 
provide definite answers to many of the questions about mast 
cell biology in health and disease which we are just starting to 
address.
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